Palvella Therapeutics, Inc. (PVLA) fair value analysis
Nasdaq · Updated 2026-10-19
PVLA price how computed
Valuation status
No fair-value estimate yetPVLA has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for PVLA yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $120.30
- Sector
- Healthcare
- 12-month range
- $70.43–$158.13
- Market cap
- $1.73B
- From 52-week high
- -23.9%
- Shares outstanding
- 14.4M
- Rank in Healthcare by quality score
- #262 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Palvella Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for patients with dermatological and other diseases. The company operates in the United States within the broader healthcare and pharmaceutical development sector.
PVLA currently ranks #262 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.73B
- P/E (trailing)
- n/m
- EPS (TTM)
- $-4.83
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- -33.3%
- Shares outstanding
- 14.4M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 29 · oversold
- 50-day average
- $145.45
- 200-day average
- $125.20
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-10
- Last 8 quarters vs consensus
- 1 beat, 7 missed
- Quarter by quarter
- 2026-06 ▼ miss (-31.0%)
2026-03 ▼ miss (-29.0%)
2025-12 ▼ miss (-18.6%)
2025-09 ▼ miss (-21.2%)
2025-06 ▼ miss (-11.7%)
2025-03 ▲ beat (+78.2%)
2024-12 ▼ miss (-798.7%)
2024-06 ▼ miss (-9112.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 15 buy · 0 hold · 0 sell (15 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $231
- Target vs last price
- +92.0%
What our data shows for PVLA
- Shares are trading in the middle of their 12-month price range of $70.43–$158.13.
- The 14-day relative strength index sits at an oversold 29.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- PVLA's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the PVLA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for PVLA showed a shift in the Relative Strength Index this week, with the RSI moving from the neutral zone into oversold territory. The stock's valuation assessment remains under review as TickrTrends awaits completion of its full valuation analysis.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is PVLA stock undervalued?
TickrTrends has no fair-value estimate for PVLA yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is PVLA's TickrTrends verdict?
PVLA is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does PVLA compare to other Healthcare stocks?
PVLA ranks #262 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is PVLA overbought or oversold?
PVLA's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does PVLA report earnings next?
PVLA's next earnings report is scheduled for 2026-11-10, per the published earnings calendar.
Does PVLA usually beat earnings estimates?
Over its last 8 reported quarters PVLA beat the consensus estimate 1 times and missed 7 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PVLA?
Of 15 analysts covering PVLA, 15 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $231 (+92.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.